dutasteride capsule / Generic mfg. - LARVOL DELTA

Male and female pattern hair loss. (PubMed, Aust Prescr) - "Pharmacological treatments for female pattern hair loss include minoxidil (topical and oral) and antiandrogens such as spironolactone. For male pattern hair loss, minoxidil and 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride) can be used. Combination therapy is commonly employed, with clinical improvement typically requiring a minimum of 6 months. Supplements and other treatments have varying levels of evidence, and counselling is important to help patients make informed decisions about their management."

Journal • Review • Alopecia • Immunology

A Canadian Consensus on androgenetic alopecia: approach and management (CDA 2025) - "As a result, 7 interventions are recommended with consensus for the management of AGA (oral dutasteride; oral finasteride; topical finasteride; topical minoxidil; PRP; microneedling; oral minoxidil). Five interventions are recommended with near consensus (intralesional dutasteride; ketoconazole shampoo; laser; aminexil; topical product (including shampoos) as part of a regimen) and 17 are not recommended with consensus for the management of AGA (adenosine; cetirizine; carboxytherapy; test shampoo; amla syrup; microfilament thread; Nourkrin; injectable minoxidil; mesotherapy; caffeine; ceramide; topical herbal formulations; piroctone olamine shampoo or leave-on; rosemary oil; shampoo and lotion hair care products containing fermented papaya, fermented mangosteen, and caffeine; bFGF; flutamide)."

Alopecia • Immunology

The Sinister Side of 5 Alpha Reductase Inhibitor Use: Drug-Induced Melasma (CDA 2025) - "Finasteride and dutasteride, 5-alpha reductase inhibitors (5-ARIs), are off-label treatments for androgen-related conditions in women, and on-label treatments for androgenetic alopecia and benign prostatic hypertrophy in men...Case 1 : A 53-year-old healthy woman was prescribed oral finasteride (2.5 mg daily, later increased to 5 mg) and topical minoxidil compound for frontal fibrosing alopecia (FFA)...She was prescribed acitretin as a non-immunosuppressive alternative for her FFA. Case 2 : A 66-year-old male with a history of prostate pathology presented with one year history of melasma on his forehead and temples, treated unsuccessfully with hydroquinone, tretinoin, and fluocinonide. Despite trials of cysteamine, tretinoin, and oral tranexamic acid, his melasma persisted... These cases highlight the potential for 5-ARIs to induce melasma in both men and women taking finasteride without prior melasma. Dermatologists should consider this rare side effect when assessing..."

Alopecia • Benign Prostatic Hyperplasia • Dermatology • Dermatopathology • Fibrosis • Immunology • Sexual Disorders

Similar Risk of Sexual Dysfunction in Androgenetic Alopecia Patients Treated With Dutasteride vs. Finasteride: A Retrospective Cohort Database Study. (PubMed, Int J Dermatol) - No abstract available

Journal • Retrospective data • Alopecia • Immunology • Sexual Disorders

Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis. (PubMed, Eur J Clin Pharmacol) - "Although our study does not imply causality, this findings suggest a statistically significant disproportionality in reports of suicidality and depression associated with finasteride use and increased signal risks of suicidality and depression highlighting the need for further large-scale epidemiological studies to confirm these findings and investigate the underlying mechanisms."

Adverse events • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry • Suicidal Ideation

Methodological concerns in 'dutasteride in the treatment of frontal fibrosing alopecia'. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Alopecia • Fibrosis • Immunology

Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series (SID 2025) - "Response to oral therapies is likely multifactorial and influenced by age, EIA medication, treatment duration, and other patient factors. Prospective controlled studies exploring treatment efficacy for EIA and patient factors associated with better response to oral therapies are warranted."

Clinical • Alopecia • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Oncology • Solid Tumor • ER

Estrogenic effects of 5-alpha-reductase inhibitors in male androgenetic alopecia patients (SID 2025) - "TriNetX Research Network was queried for AGA males (ICD-10: L64, L65.8, L65.9) treated with finasteride or dutasteride from 2004–2024, with 5ARI-naïve AGA males used as controls. Our findings indicate increased risk of gynecomastia and ED in 5ARI-treated AGA males, suggesting possible testosterone aromatization contributing to estrogenic effects. The observed associations underscore the need for physicians to consider the potential hormonal side effects when prescribing 5ARIs for male AGA and to discuss these risks with patients as part of shared decision-making."

Clinical • Addiction (Opioid and Alcohol) • Alopecia • Erectile Dysfunction • Genetic Disorders • Immunology • Infertility • Obesity • Sexual Disorders

Exposure to 5-Alpha Reductase Inhibitors and Spironolactone Is Not Associated With Increased Odds of Gynecologic Tumors in a Large Cohort Study of Patients With Alopecia. (PubMed, Int J Dermatol) - No abstract available

Journal • Alopecia • Gynecologic Cancers • Immunology • Oncology

Computational drug discovery of potential 5α-reductase phytochemical inhibitors and hair growth promotion using in silico techniques. (PubMed, Front Bioinform) - "The Food and Drug Administration (FDA) has approved two 5-alpha reductase (5-AR) inhibitors-finasteride and dutasteride-for treating this condition...We found that 6 molecules-Jamogenin, Neodiosgenin, Chlorogenic acid, Rutin, Riboflavin, and Ursolic acid-are effective in binding to 5-AR. Additionally, our in silico studies revealed that vesicle-entrapped JAMOGENIN, which has a stronger bond with 5-AR, is more stable than its unencapsulated form. Therefore, these 6 molecules, particularly JAMOGENIN, should be considered for experimental analysis in both their unencapsulated and nanocarrier-encapsulated states to promote hair follicle growth."

Journal • Alopecia • Immunology

Nurses' and midwives' knowledge and safe-handling practices related to hazardous drugs: A cross-sectional study. (PubMed, Int J Nurs Stud Adv) - "The hazardous drugs chloramphenicol, colchicine, and dutasteride were frequently not identified as hazardous (80.6 %, 73.8 %, and 68.2 %, respectively). Nurses and midwives did not always recognise hazardous drugs, and, although they were confident in using appropriate personal protective equipment, some reported never wearing it. A multi-faceted multidisciplinary intervention is needed to improve both knowledge and practice for handling both cytotoxic and non-cytotoxic drugs by nurses and midwives."

Journal • Observational data

Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch. (PubMed, Eur J Pharm Biopharm) - "Bicalutamide (BIC) is a testosterone blocker that, due to its peripheral tissue selectivity, offers the advantage of fewer side effects compared to other antiandrogens such as finasteride or dutasteride. Ex vivo studies demonstrated the efficacy of BIC-LVs@DMAPs to improve the skin retention of BIC, while in vitro cytotoxicity results ensured their safety profile. Overall, these results pave the way for further in vivo studies and clinical application to improve the current early stages androgenetic alopecia topical treatments."

Journal • Preclinical • Alopecia • Immunology

Response to Venkatesh et al.'s "Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: a single-center retrospective cohort study". (PubMed, J Am Acad Dermatol) - No abstract available

HEOR • Journal • Retrospective data • Alopecia • Breast Cancer • Immunology • Oncology • Solid Tumor

Enhanced Acute Muscle Activation in ALS Patients Following Liposomal Curcumin, Resveratrol, and Dutasteride Administration. (PubMed, Pharmaceuticals (Basel)) - "For fasciculations, there was an increase in the total activation of the upper muscles in the IG (p = 0.017; g = -0.86) and for the lower muscles in the CG (p = 0.037; g = -0.68). The pattern of muscle activation remained constant in the IG but experienced variations in the CG."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders

Kyoh® Rocket Leaf Extract Regulates Proliferation and VEGF and FGF7 Expression in Human Dermal Follicle Papilla Cells. (PubMed, Molecules) - "Current treatments for androgenetic alopecia, such as those based on drugs like Minoxidil, Finasteride, or Dutasteride, have been associated with a variety of side effects, such as irritation, contact dermatitis, scalp pruritus, burning, etc. In this regard, plant extracts have emerged as promising alternatives to available chemical-based treatments for androgenetic alopecia given their efficacy, customer acceptability, and potentially minimized side effects. Moreover, Kyoh® increased the gene expression of NRF2 (Nuclear factor erythroid 2-related factor 2) by 71.2%, which encodes for a protein participating in the antioxidant response. Overall, our study shows that flavonol-rich rocket extract (Kyoh®) is a promising treatment for promoting hair growth, demonstrated by its proliferation-promoting effect, potential antioxidant priming, and induction of the expression of growth factors associated with hair growth and health."

Journal • Alopecia • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • FGF • FGF7 • NFE2L2 • VEGFA

Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. (PubMed, JAAD Int) - No abstract available

Journal • Alopecia • Immunology

Comparison of Intraoperative Blood Loss in Monopolar Transurethral Resection of the Prostate With and Without Two Weeks of Preoperative Dutasteride. (PubMed, Cureus) - "The study's findings indicate a significant superiority of administering dutasteride before surgery for a duration of two weeks. A substantial reduction in both intraoperative blood loss and blood loss per gram is seen in patients who underwent monopolar TURP with dutasteride."

Journal • Benign Prostatic Hyperplasia

Shifts in Diagnostic Approaches for Prostate Cancer: The Impact of MRI-informed Biopsies on Low-Risk Cancer Detection (AUA 2025) - "Patients receiving dutasteride treatment (n=10) were excluded... The increasing use on MRI-informed biopsies in the diagnosis of PCa has shifted clinical practice, potentially contributing to the reduced detection of low-risk PCa."

Biopsy • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urology

Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results from REDUCE study (AUA 2025) - "Since BPH is the most common cause of lower urinary tract symptoms (LUTS), we investigated whether IR is also linked to the incidence and progression of LUTS in the REDUCE study, a 4-year randomized trial of dutasteride vs. placebo for prostate cancer prevention... We found that although IR was linked to larger prostate volumes, it was not an independent risk factor of LUTS development or progression despite the known associations between BPH and LUTS. Further studies are needed to explore the complex interactions between IR, BPH, and LUTS."

Benign Prostatic Hyperplasia • Diabetes • Genito-urinary Cancer • Metabolic Disorders • Oncology • Prostate Cancer • Solid Tumor

Beyond Obstruction: The Effect of Dutasteride on Irritative Voiding Symptoms in Men with Lower Urinary Tract Symptoms (AUA 2025) - "In addition to relieving obstructive symptoms, these results suggest that dutasteride provides modest relief for irritative voiding symptoms in men with bothersome, moderate-to-severe LUTS. Given the challenges in managing irritative symptoms, additional medical therapy may be necessary to achieve optimal symptom control."

Benign Prostatic Hyperplasia • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia (clinicaltrials.gov) - P3 | N=288 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P3 trial • Alopecia • Dermatology • Immunology

No increased risk of mood disorders in male androgenetic alopecia patients treated with dutasteride and finasteride: a retrospective cohort database study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Alopecia • CNS Disorders • Immunology • Mood Disorders • Psychiatry

Frontal Fibrosing Alopecia in Men: A Review of the Literature. (PubMed, J Clin Med) - "Oral 5-ARi (dutasteride) combined with topical corticosteroids and calcineurin inhibitors form the first line. Additional treatments include intralesional corticosteroids, oral isotretinoin for facial papules, and minoxidil for associated AGA... FFA in men presents with distinct clinical features and challenges in diagnosis, often overlapping with other alopecia. Further studies are needed to validate diagnostic criteria and evaluate treatment efficacy in this underrepresented population."

Journal • Review • Aesthetic Medicine • Alopecia • Fibrosis • Immunology • Lichen Planus • Transplantation • CYP1B1 • HLA-B

Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters. (PubMed, Clin Exp Reprod Med) - "Receiver operating characteristic analysis showed the cutoff values for persistent impairment of semen volume and total sperm motility to be 17.8 and 20.3 months, respectively. Long-term use of dutasteride may lead to male infertility by persistently impairing semen volume and sperm motility."

Journal • Alopecia • Immunology • Infertility • Sexual Disorders

Finasteride Use: Evaluation of Depression and Suicide Risk. (PubMed, J Cosmet Dermatol) - "The study found no significant correlation between oral finasteride and depression/suicide reports from 2006 to 2011 but noted a significant number of such reports in 2013-2018 and 2019-2023. This increase may be linked to heightened awareness of AEs following the recognition of so-called PFS in 2012."

Journal • Alopecia • Benign Prostatic Hyperplasia • CNS Disorders • Depression • Immunology • Mood Disorders • Psychiatry • Suicidal Ideation